

Fecha del CVA	21/02/2021
---------------	------------

Parte A. DATOS PERSONALES

Nombre y Apellidos	Mohammed Rafii-El-Idrissi Benhnia		
DNI	49032498V	Edad	
Núm. identificación del investigador	Researcher ID	F-3019-2015	
	Scopus Author ID	6603261906	
	* Código ORCID	0000-0001-7405-9476	

* Obligatorio

A.1. Situación profesional actual

Organismo	Universidad de Sevilla		
Dpto. / Centro	/ Facultad de Medicina & INSTITUTO DE BIOMEDICINA DE SEVILLA		
Dirección	Instituto de Biomedicina de Sevilla (IBiS)/Hospital Universitario Virgen del Rocío, Avd. Manuel Siurot s/n, 41013, Sevilla		
Teléfono	(0034) 693843894	Correo electrónico	rafiim@us.es
Categoría profesional	Profesor Contratado Doctor	Fecha inicio	2017
Palabras clave	Química; Biomedicina		

A.2. Formación académica (título, institución, fecha)

Licenciatura/Grado/Doctorado	Universidad	Año
BIOQUIMICA CLINICA	UNIVERSIDAD DE SEVILLA	2002
CAP	UNIVERSIDAD DE SEVILLA	2001
HOMOLOGACION DEL TITULO DE LICENCIATURA DE BIOLOGIA	MINISTERIO DE EDUCACION Y CIENCIA	2000
LICENCIATURA: BIOLOGIA GENERAL	UNIVERSIDAD MOULAY ISMAIL	1992
DIPLOMA DE SECUNDO CICLO: BIOLOGIA Y GEOLOGIA	UNIVERSIDAD MOULAY ISMAIL	1990

A.3. Indicadores generales de calidad de la producción científica

- Sexenios: 2. Quinquenios: 1
- Tesis dirigidas en los últimos 10 años: 2 en proceso, previsto para 2021
- TFM dirigidos: 3 y 2 en proceso. TFG dirigidos: 4.- Spin Offs: 1
- Citas totales: 2470 (Google Académico, GA), **1857 (Web of Science, WOS)**
- Promedio de citas/año durante los últimos 10 años: 142 (GA).
- Promedio citas por artículo: 54,7
- Publicaciones totales: 33. Q1: 21; y D1: 12. Índice **H: 18** (GA) 18 (Scopus). i10: 26
- **Impact Factor (IF):** 1.-Journal of Microbiology, Immunology and Infection, 2019. **IF: 3,49 (Q1)**. 2.-Viral immunology, 2016. **IF: 1,432 (Q3)**. 3.-Clinical Microbiology and Infection. 2016. **IF: 4,575 (Q1)**. 4.-J Gerontol A Biol Sci Med; 2016. **IF: 5.416 (D1)**. 5.-PLoS ONE, 2016 **IF: 2,87 (Q1)**. 6.-The Journal of Infectious Diseases. 2015. **IF: 6,344 (D1)**. 7.-PloS Pathogen. 2015. **IF: 7,57 (D1)**. 8.-Clin Microbiol Infect. 2015. **IF: 4,575 (Q1)**. 9.-Antiviral Res. 2015. **IF: 3.925 (Q1)**. 10.-Structure. 2014. **FI: 5,237 (Q1)**. 11.-Antiviral Res. 2014. **IF: 4.439 (Q1)**

Parte B. RESUMEN LIBRE DEL CURRÍCULUM

Doctor in Biology, Assistant Professor, Department of Medical Biochemistry and Molecular Biology and Immunology of the University of Seville. My professional activity as a teacher began since my incorporation as a Ramón y Cajal researcher in 2011 with a total of 1629 hours in 9 years teaching various subjects of Human Biochemistry, abasic and clinical Immunology and immunopathology for the Degrees of Biomedicine, Medicine, Nursing, Physiotherapy and Science of the Physical and Sports Activity, Physiotherapy, Health Engineering, Biochemistry and Biology. Moreover, I coordinate Immunovirology of HIV and clinical immunology for the Master in Medical Research. I am coordinator of several subjects of the degree of biochemistry and three of the Master. I have supervised three TFM and four TFG, and I am currently directing two PhD Thesis.

Academic background: I completed my Biology Degree at the Faculty of Science of the University of Moulay Ismail Morocco in 1992 and defended my PhD Thesis at the University of Seville obtaining the qualification of Outstanding "cum laude" by Unanimity in February 2002. My scientific career began in 1993 by joining Dr. Juan Miguel Guerrero and Dr. Juan Ramón Calvo research group as a predoctoral fellow resulted in 9 articles in peer-review publications. Postdoctoral fellow in the US at "Albany Medical College (AMC), Albany, NY" March 2003-April 2006 and at "the Jolla Institute for Allergy and Immunology (LJI)" April 2006-December 2008. Scientific Associate in "LJI", one of the 5 best centers in biomedical and immunology research in the world (Data provided by Thomson Reuters from its Essential science indicator database 2000-2010), from January 2009 to October 2011. I get introduced to topics such as immunology, virology, vaccinology and infectious diseases. During my professional activity in the US in the laboratory of Dr. Sellati (AMC) and Dr. Crotty (LJI) I coordinated several projects and supervised several postdoctoral and technical staff, whose activities contributed to publishing impressive works in journals with a high impact factor with an average of 8.2 / publication; and received comments from several journalists in the US and the Dana Foundation. Since my incorporation at the University of Seville and the Institute of Biomedicine of Seville (IBiS), due to my highly qualified academic achievements and my skills as an independent researcher, I have formed a research team with clinical and basic scientists integrated in the Group of Immunovirological Studies of Dr Manuel Leal (CTS-590). I have also obtained 4 national and international research projects as principal investigator and one as collaborator. I am a member of the Spanish, European and American virologic associations; and of the Spanish Network for AIDS Research (RIS) in the Immunopathogeny and Vaccines programs, RD16/0025/0020 call. I presented my inventions in several national and international scientific congresses and I have been able to publish 32 articles in journals with high impact factor such as Nature Immunology, Immunity, PNAS, Plos Pathogen, J of Virology, Structure, J of Immunology, and Antiviral Therapy etc. with an h-index of 18 and a cumulative impact factor of 172.

Parte C. MÉRITOS MÁS RELEVANTES (ordenados por tipología)

C.1. Publicaciones

AC: Autor de correspondencia; (nº x / nº y): posición firma solicitante / total autores

- 1 Artículo científico.** LRuiz-de-León M.J; Jiménez-Sousa M.A.; Moreno S.; et al;. 2019. Lower expression of plasma-derived exosome miR-21 levels in HIV-1 elite controllers with decreasing CD4 T cell count. *Journal of Microbiology, Immunology and Infection*. 52-4, pp.667-671.
- 2 Artículo científico.** Idefonso Pulido; Miguel Genebat; Ana I. Alvarez-Rios; Rebeca S. De Pablo-Bernal; Mohammed Rafii-El-Idrissi Benhnia; Yolanda M. Pacheco; Ezequiel Ruiz-Mateos; Manuel Leal. 2016. Immunovirological Efficacy of Once-Daily Maraviroc Plus Ritonavir-Boosted Atazanavir After 48 Weeks in Naive HIV-Infected Patients *VIRAL IMMUNOLOGY*. Mary Ann Liebert, Inc.. 29-8, pp.471-477.
- 3 Artículo científico.** Pozo-Balado M; Rosado I; Méndez G; et al; Pacheco Yolanda. 2016. Maraviroc contributes to the restoration of the homeostasis of regulatory T-cell subsets in antiretroviral-naïve HIV-infected subjects *Clinical Microbiology and Infection*. Elsevier B.V.. 22-5, pp.461. ISSN 1470-9465.

- 4 **Artículo científico.** De Pablo-Bernal RS; Cañizares J; Rosado I; et al; Ruiz-Mateos E.2016. Monocyte phenotype and polyfunctionality are associated with elevated soluble inflammatory markers, cytomegalovirus infection and functional and cognitive decline in the elderly. *J Gerontol A Biol Sci Med Sci.* 71-5, pp.610-618.
- 5 **Artículo científico.** De Pablo-Bernal RS; Cañizares J; Genebat M; et al; Ruiz-Mateos E. 2016. Phenotype and polyfunctional deregulation involving IL-6 and IL-10-producing monocytes of HIV-infected patients on HAART differ from those of aging. *The Journal of Infectious Diseases.* Oxford Journals. 213, pp.999-1007.
- 6 **Artículo científico.** Egaña-Gorroño L.; Guardo A.C; Bargalló M.E.; Planet E.; Vilaplana E; Escribà T; ; Pérez I.2016. MicroRNA profile in CD8+ T-lymphocytes from HIV-infected individuals: Relationship with antiviral immune response and disease progression. *PLoS ONE.* 11-5.
- 7 **Artículo científico.** Genebat M; de Pablo-Bernal RS; Pulido I; et al; Leal M.2015. Maraviroc Clinical Test (MCT) as an alternative tool to decide CCR5-antagonists prescription in naïve HIV-infected patients. *Antiviral Res.* 121, pp.94-96.
- 8 **Artículo científico.** Michael H. Matho; Andrew Schollossman; Xiangzhi Meng; et al; Dirk Zajonc. 2015. Structural and functional characterization of anti-A33 antibodies reveal a potent cross-species orthopoxviruses neutralizer. *PloS Pathogen.* 11, pp.e1005148.
- 9 **Artículo científico.** Machmach K.; Abad-Molina C; Romero-Sánchez MC.; et al; Ruiz-Mateos E.2015. IFNL4 ss469415590 polymorphism is associated with unfavourable clinical and immunological status in HIV-infected individuals. *Clin Microbiol Infect.*21-3.
- 10 **Artículo científico.** Romero-Sánchez MC; Alvarez-Ríos AI; Bernal-Morell E; et al; VIH-GEMUVIH Región de Murcia Study Group. 2014. Maintenance of virologic efficacy and decrease in levels of beta 2-microglobulin, soluble CD40L and soluble CD14 after switching previously treated HIV-infected patients to an NRTI-sparing dual therapy. *Antiviral Res.* 111, pp.26-32.
- 11 **Artículo científico.** Inbal Sela-Culang; Mohammad Rafii-El-Idrissi Benhnia; Michael H. Matho; et al; and Bjoern Peters. 2014. Using a Combined Computational-Experimental Approach to Predict Antibody-Specific B Cell Epitopes. *Structure CELL.* 22-4.

C.2. Proyectos

- 1 NUEVOS METODOS PARA ERRADICAR EL VIH Y AUMENTAR LA RESPUESTA INMUNE A LA VACUNA DEL VHB USANDO REDES METAL ORGANICAS COMO AGENTES ENCAPSULANTES Mohammed Rafii El Idrissi Benhnia. (Universidad de Sevilla.). 01/01/2020-31/12/2020. 5.000 €.
- 2 Papel de las células T CD4+ foliculares circulantes y de linfocitos B en la mejora de la inmunidad humoral y el control espontaneo del VIH en individuos controladores de elite. Mohammed Rafii El Idrissi Benhnia. (Universidad de Sevilla.). 01/01/2018-31/12/2019. 5.000 €.
- 3 PREDICCIÓN DE LA RESPUESTA DE ANTICUERPOS ALTAMENTE NEUTRALIZANTE Y CONTROL DEL VIH EN LA COLABORACIÓN DE CELULAS TCD4+(TFH) Y AUSENCIA DE DISFUNCIONES DE LINFOCITOS B Instituto de Salud Carlos III. Mohammed Rafii-El-Idrissi BENHIA. (Universidad de Sevilla). 01/01/2014-30/12/2017. 69.450 €.
- 4 Role of Fc receptors in generating immune protection in vivo against Vaccinia virus MICINN. MOHAMMED RAFII-EL-IDRISSI BENHIA. (Universidad de Sevilla). 01/11/2011-31/10/2016. 192.480 €.

C.3. Contratos

- 1 Clinical Trial #NCT04710199 "Proof-of-concept Trial to Evaluate the Safety and Efficacy of Maraviroc in Severe Acute Respiratory Syndrome (SARS) Coronavirus-2 (CoV-2) Infected Patients Hospitalized for COVID-19" (COVIMAR) CENTRO DE ACUSTICA APLICADA Y EVALUACION NO DESTRUCTIVA. Ezequiel Ruiz-Mateos. Desde 10/02/2021.
- 2 Role of a combined antiretroviral treatment including maraviroc in the response to hepatitis B and A virus vaccine ViiV Healthcare. Mohammed Rafii El Idrissi Benhnia. 31/08/2016-31/08/2017. 50.000 €.

- 3 Effect of a NRTI-sparing regime containing Darunavir on cellular senescence, inflammatory biomarkers Janssen-Cilag, S.A.. Mohammed Rafii El Idrissi Benhnia. 03/09/2014-03/09/2015. 30.000 €.

C.4. Patentes

Manuel Leal Noval; Yolanda Pacheco; Ezequiel Ruiz Mateos Carmona; Mohammed rafii El Idrissi Benhnia. B90184540. AGING TECHNOLOGIES & DIAGNOSTICS S.L España. 2015.